Inmune Bio Stock Performance
| INMB Stock | USD 4.87 0.11 2.31% |
The company retains a Market Volatility (i.e., Beta) of 2.39, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, INmune Bio will likely underperform. At this point, INmune Bio has a negative expected return of -0.47%. Please make sure to check out INmune Bio's maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if INmune Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days INmune Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 2.31 | Five Day Return (2.60) | Year To Date Return (56.60) | Ten Year Return (39.05) | All Time Return (39.05) |
1 | Acquisition by Moss David J of 7690 shares of INmune Bio at 6.4 subject to Rule 16b-3 | 09/12/2024 |
2 | INmune Bio, Inc.s top owners are individual investors with 44 percent stake, while 23 percent is held by institutions | 09/13/2024 |
3 | Acquisition by Moss David J of 18028 shares of INmune Bio at 9.152 subject to Rule 16b-3 | 09/25/2024 |
4 | Inmune Bio CFO buys 52,868 in company stock | 09/30/2024 |
5 | Where are the Opportunities in - Stock Traders Daily | 10/07/2024 |
6 | INmune Bio, Inc. Short Interest Update | 10/16/2024 |
7 | INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 | 10/24/2024 |
8 | Acquisition by Tesi Raymond Joseph of 130000 shares of INmune Bio subject to Rule 16b-3 | 10/29/2024 |
9 | INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update | 10/31/2024 |
10 | INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimers Disease | 11/13/2024 |
11 | Scotiabank Initiates Coverage of INmune Bio with Sector Outperform Recommendation - MSN | 11/20/2024 |
| Begin Period Cash Flow | 52.2 M | |
| Free Cash Flow | -12 M |
INmune |
INmune Bio Relative Risk vs. Return Landscape
If you would invest 705.00 in INmune Bio on August 25, 2024 and sell it today you would lose (218.00) from holding INmune Bio or give up 30.92% of portfolio value over 90 days. INmune Bio is currently does not generate positive expected returns and assumes 4.3168% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than INmune, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
INmune Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for INmune Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as INmune Bio, and traders can use it to determine the average amount a INmune Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.11
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INMB |
Estimated Market Risk
| 4.32 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.47 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average INmune Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of INmune Bio by adding INmune Bio to a well-diversified portfolio.
INmune Bio Fundamentals Growth
INmune Stock prices reflect investors' perceptions of the future prospects and financial health of INmune Bio, and INmune Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on INmune Stock performance.
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (989.21) % | ||||
| Current Valuation | 77.34 M | ||||
| Shares Outstanding | 22.17 M | ||||
| Price To Earning | (7.51) X | ||||
| Price To Book | 2.79 X | ||||
| Price To Sales | 2,571 X | ||||
| Revenue | 155 K | ||||
| Gross Profit | 374 K | ||||
| EBITDA | (29.74 M) | ||||
| Net Income | (30.01 M) | ||||
| Cash And Equivalents | 61.21 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 10.44 M | ||||
| Debt To Equity | 0.22 % | ||||
| Current Ratio | 30.87 X | ||||
| Book Value Per Share | 1.74 X | ||||
| Cash Flow From Operations | (11.98 M) | ||||
| Earnings Per Share | (2.18) X | ||||
| Market Capitalization | 107.98 M | ||||
| Total Asset | 57 M | ||||
| Retained Earnings | (121.02 M) | ||||
| Working Capital | 21.48 M | ||||
| Current Asset | 8.38 M | ||||
| Current Liabilities | 721.01 K | ||||
About INmune Bio Performance
By analyzing INmune Bio's fundamental ratios, stakeholders can gain valuable insights into INmune Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if INmune Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if INmune Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.74) | (0.78) | |
| Return On Capital Employed | (0.77) | (0.73) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.79) | (0.75) |
Things to note about INmune Bio performance evaluation
Checking the ongoing alerts about INmune Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for INmune Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| INmune Bio generated a negative expected return over the last 90 days | |
| INmune Bio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 155 K. Net Loss for the year was (30.01 M) with profit before overhead, payroll, taxes, and interest of 374 K. | |
| INmune Bio currently holds about 61.21 M in cash with (11.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41. | |
| INmune Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 29.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Scotiabank Initiates Coverage of INmune Bio with Sector Outperform Recommendation - MSN |
- Analyzing INmune Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether INmune Bio's stock is overvalued or undervalued compared to its peers.
- Examining INmune Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating INmune Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of INmune Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of INmune Bio's stock. These opinions can provide insight into INmune Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |